McKesson FY27 Q1 adjusted EPS rises 20% to $9.93; revenue increases 8% to $105.4 billion
MCK•Quarterly results
McKesson posted fiscal 2027 first-quarter revenue of $105.4 billion, up 8%, while GAAP diluted EPS fell 18% to $5.15.
Net income attributable to shareholders dropped 22% to $614 million; management cited a $293 million redemption value adjustment tied to Medical-Surgical Solutions.
Non-GAAP adjusted diluted EPS climbed 20% to $9.93, supported by operational growth in North American Pharmaceutical and Oncology & Multispecialty.
Outlook and dividend
McKesson raised its full-year non-GAAP adjusted diluted EPS outlook to $44.20-$45.00.
The quarterly dividend was increased 15% to $0.94 per share.
Cash flow and shareholder returns
Cash used in operations was $220 million, driving negative free cash flow of $372 million; McKesson returned to shareholders.
